CTOs on the Move

CinRx Pharma

www.cinrx.com

 
CinRx Pharma is a multi-asset biotech company focusing on advancing novel therapeutics that address large unmet medical needs.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cinrx.com
  • 5375 Medpace Way
    Cincinnati, AK USA 45227
  • Phone: 844.531.1834

Executives

Name Title Contact Details

Funding

CinRx Pharma raised $10M on 11/28/2017

Similar Companies

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.

CPS Instruments

CPS Instruments is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arzeda

Arzeda The Protein Design Company is a synthetic biology company.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

Mirus Bio

Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.